CHC Healthcare Group (承業醫) reported a strong November revenue of NT$394 million, representing a 16.68% monthly increase and a 32.63% year-on-year (YoY) growth. As the industry enters its traditional year-end delivery peak, analysts expect December to be the strongest month of the year, pushing Q4 to an annual high.

Business Unit Updates:

• Irradiation Services: Shin-Ho Biotech, a subsidiary of CHC, has successfully passed certifications from semiconductor and medical device clients for its irradiation plant. Production is expected to commence in Q1 2026, with a goal of achieving profitability within the year.
• Retail Expansion: The subsidiary Fukang Pharmacy maintains its target to file for IPO by the end of 2026. The chain aims to reach 100 stores before the filing.
• Project Delivery: While some high-end medical equipment acceptance (inspection) may be deferred to January 2026 due to pending building occupancy permits at client hospitals, the significant volume of deliveries in December will sustain high Q4 revenue.

Resource: 業績牌出色 承業醫雀躍